13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001727492
Total reported value
$2.1B
$2.1B
12 檔
11.0%
During the Q3 2024 filing period, Caligan Partners LP (CIK: 0001727492) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $2.1B across 12 reported positions.
In Q3 2024, Caligan Partners LP adopted a defensive or profit-taking posture, trimming 6 positions and completely liquidating 1 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | LQDA | Liquidia CORP | Stock-Other | 25.73% | +10.06% | -21.64% | |
| 2 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 13.10% | — | -22.07% | |
| 3 | EXEL | Exelixis Inc | Stock-Healthcare | 12.55% | -0.45% | — | |
| 4 | EOLS | Evolus Inc | Stock-Other | 11.26% | — | +1.19% | |
| 5 | ANIK | Anika Therapeutics Inc | Stock-Other | 11.24% | -0.39% | -0.06% | |
| 6 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 8.16% | -0.04% | +12.63% | |
| 7 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 6.22% | — | -43.82% | |
| 8 | YMABUSD | Y-mabs Therapeutics Inc | Stock-Other | 4.98% | — | +105.34% | |
| 9 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 3.77% | -5.00% | EXIT | |
| 10 | NBP | Novabridge Biosciences | Stock-Other | 1.38% | — | +3.69% | |
| 11 | ENTA | Enanta Pharmaceuticals Inc | Stock-Other | 1.06% | — | -69.08% | |
| 12 | OTLK | Outlook Therapeutics Inc | Stock-Other | 0.54% | — | -36.26% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | VRNA | Verona Pharma PLC - Adr | +6.9% | -22.07% | Trim |
| 2 | EOLS | Evolus Inc | +5.8% | +1.19% | Add |
| 3 | EXEL | Exelixis Inc | +4.5% | — | Unchanged |
| 4 | YMABUSD | Y-mabs Therapeutics Inc | +3.3% | +105.34% | Add |
| 5 | AGIO | Agios Pharmaceuticals Inc | +3% | +12.63% | Add |
| 6 | ANIK | Anika Therapeutics Inc | +2.7% | -0.06% | Trim |
| 7 | MLYS | Mineralys Therapeutics Inc | +1.7% | +31.56% | Add |
| 8 | NBP | Novabridge Biosciences | +0.1% | +3.69% | Add |
| 9 | OTLK | Outlook Therapeutics Inc | -0.3% | -36.26% | Trim |
| 10 | BCRX | Biocryst Pharmaceuticals Inc | -0.4% | -43.82% | Trim |
| 11 | ENTA | Enanta Pharmaceuticals Inc | -2.1% | -69.08% | Trim |
| 12 | LQDA | Liquidia CORP | -3.3% | -21.64% | Trim |
| 13 | ✓ | Alimera Sciences Inc | -21.9% | EXIT | Sold out |
According to official SEC Form 13F filings, Caligan Partners LP reported a total U.S. public equity portfolio value of $2.1B across 12 disclosed positions in Q3 2024.
During Q3 2024, Caligan Partners LP's top holdings by market value included LQDA (25.7%)、VRNA (13.1%)、EXEL (12.6%). The largest single position, LQDA, represented 25.7% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including LQDA, VRNA, EXEL) accounted for 11.0% of total reported equity market value during Q3 2024.
Top Position Liquidated / Trimmed
ALIMERA SCIENCES INC
前期市值: $93.6M
In Q3 2024, Caligan Partners LP made 12 total portfolio adjustments, initiating 0 new buys, adding to 5 positions, trimming 6 holdings, and fully liquidating 1 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.